Follow
Jean-François Laprise
Jean-François Laprise
Centre de recherche du CHU de Québec
Verified email at uresp.ulaval.ca
Title
Cited by
Cited by
Year
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
M Brisson, JJ Kim, K Canfell, M Drolet, G Gingras, EA Burger, D Martin, ...
The Lancet 395 (10224), 575-590, 2020
5822020
Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries
K Canfell, JJ Kim, M Brisson, A Keane, KT Simms, M Caruana, EA Burger, ...
The Lancet 395 (10224), 591-603, 2020
4282020
Potential cost‐effectiveness of the nonavalent human papillomavirus (HPV) vaccine
M Drolet, JF Laprise, MC Boily, EL Franco, M Brisson
International Journal of Cancer 134 (9), 2264-2268, 2014
195*2014
Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model–based analysis
N Van de Velde, MC Boily, M Drolet, EL Franco, MH Mayrand, EV Kliewer, ...
Journal of the National Cancer Institute 104 (22), 1712-1723, 2012
1702012
Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States
M Brisson, JF Laprise, HW Chesson, M Drolet, T Malagón, MC Boily, ...
Journal of the National Cancer Institute 108 (1), djv282, 2016
1012016
The estimated direct lifetime medical costs of sexually transmitted infections acquired in the United States in 2018
HW Chesson, IH Spicknall, A Bingham, M Brisson, ST Eppink, ...
Sexually Transmitted Diseases 48 (4), 215-221, 2021
872021
Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model
M Jit, M Brisson, JF Laprise, YH Choi
Bmj 350, 2015
872015
Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States
JF Laprise, HW Chesson, LE Markowitz, M Drolet, D Martin, É Bénard, ...
Annals of internal medicine 172 (1), 22-29, 2020
832020
Comparing the cost-effectiveness of two-and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study
JF Laprise, M Drolet, MC Boily, M Jit, C Sauvageau, EL Franco, ...
Vaccine 32 (44), 5845-5853, 2014
812014
Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study
M Brisson, JF Laprise, M Drolet, N Van de Velde, EL Franco, EV Kliewer, ...
Vaccine 31 (37), 3863-3871, 2013
742013
Estimated prevalence and incidence of disease-associated human papillomavirus types among 15-to 59-year-olds in the United States
RM Lewis, JF Laprise, JW Gargano, ER Unger, TD Querec, HW Chesson, ...
Sexually transmitted diseases 48 (4), 273-277, 2021
622021
Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical …
M Drolet, JF Laprise, D Martin, M Jit, É Bénard, G Gingras, MC Boily, ...
The Lancet Infectious Diseases 21 (11), 1598-1610, 2021
552021
Sociodemographic inequalities in sexual activity and cervical cancer screening: implications for the success of human papillomavirus vaccination
M Drolet, MC Boily, C Greenaway, SL Deeks, C Blanchette, JF Laprise, ...
Cancer epidemiology, biomarkers & prevention 22 (4), 641-652, 2013
542013
Ultrafast laser-induced melting of glass
V Koubassov, JF Laprise, F Théberge, E Förster, R Sauerbrey, B Müller, ...
Applied Physics A 79, 499-505, 2004
542004
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling …
KT Simms, JF Laprise, MA Smith, JB Lew, M Caruana, M Brisson, ...
The Lancet Public Health 1 (2), e66-e75, 2016
512016
Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis
JF Laprise, LE Markowitz, HW Chesson, M Drolet, M Brisson
The Journal of infectious diseases 214 (5), 685-688, 2016
502016
Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine
HW Chesson, JF Laprise, M Brisson, LE Markowitz
The Journal of infectious diseases 213 (11), 1694-1700, 2016
382016
Two-dose strategies for human papillomavirus vaccination: how well do they need to protect?
M Jit, YH Choi, JF Laprise, MC Boily, M Drolet, M Brisson
Vaccine 32 (26), 3237-3242, 2014
362014
Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review
G Gingras, MH Guertin, JF Laprise, M Drolet, M Brisson
PloS one 11 (9), e0163880, 2016
352016
The impact of human papillomavirus catch-up vaccination in Australia: implications for introduction of multiple age cohort vaccination and postvaccination data interpretation
M Drolet, JF Laprise, JML Brotherton, B Donovan, CK Fairley, H Ali, ...
The Journal of Infectious Diseases 216 (10), 1205-1209, 2017
342017
The system can't perform the operation now. Try again later.
Articles 1–20